Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party

Show simple item record

dc.contributor.author Scheid, C.
dc.contributor.author de Wreede, L.
dc.contributor.author van Biezen, A.
dc.contributor.author Koenecke, C.
dc.contributor.author Gohring, G.
dc.contributor.author Volin, L.
dc.contributor.author Maertens, J.
dc.contributor.author Finke, J.
dc.contributor.author Passweg, J.
dc.contributor.author Beelen, D.
dc.contributor.author Cornelissen, J. J.
dc.contributor.author Itälä-Remes, M.
dc.contributor.author Chevallier, P.
dc.contributor.author Russell, N.
dc.contributor.author Petersen, E.
dc.contributor.author Milpied, N.
dc.contributor.author Espiga, C. Richard
dc.contributor.author Peniket, A.
dc.contributor.author Sierra, J.
dc.contributor.author Mufti, G.
dc.contributor.author Crawley, C.
dc.contributor.author Veelken, J. H.
dc.contributor.author Ljungman, P.
dc.contributor.author Cahn, J. Y.
dc.contributor.author Alessandrino, E. P.
dc.contributor.author de Witte, T.
dc.contributor.author Robin, M.
dc.contributor.author Kroeger, N.
dc.date.accessioned 2017-11-20T12:42:03Z
dc.date.available 2017-11-20T12:42:03Z
dc.date.issued 2017-11
dc.identifier.citation Scheid , C , de Wreede , L , van Biezen , A , Koenecke , C , Gohring , G , Volin , L , Maertens , J , Finke , J , Passweg , J , Beelen , D , Cornelissen , J J , Itälä-Remes , M , Chevallier , P , Russell , N , Petersen , E , Milpied , N , Espiga , C R , Peniket , A , Sierra , J , Mufti , G , Crawley , C , Veelken , J H , Ljungman , P , Cahn , J Y , Alessandrino , E P , de Witte , T , Robin , M & Kroeger , N 2017 , ' Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party ' , Bone Marrow Transplantation , vol. 52 , no. 11 , pp. 1519-1525 . https://doi.org/10.1038/bmt.2017.171
dc.identifier.other PURE: 93955715
dc.identifier.other PURE UUID: 53dee486-524b-4811-9f29-89f3f23d2ce6
dc.identifier.other WOS: 000414256900006
dc.identifier.other Scopus: 85032637622
dc.identifier.uri http://hdl.handle.net/10138/228617
dc.description.abstract The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P <0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P <0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant. en
dc.format.extent 7
dc.language.iso eng
dc.relation.ispartof Bone Marrow Transplantation
dc.rights cc_by_nc_nd
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject PROGNOSTIC SCORING SYSTEM
dc.subject BONE-MARROW-TRANSPLANTATION
dc.subject ACUTE MYELOID-LEUKEMIA
dc.subject MONOSOMAL KARYOTYPE
dc.subject MDS
dc.subject CLASSIFICATION
dc.subject CYTOGENETICS
dc.subject OUTCOMES
dc.subject SOCIETY
dc.subject 3122 Cancers
dc.title Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party en
dc.type Article
dc.contributor.organization Clinicum
dc.contributor.organization Department of Oncology
dc.contributor.organization HUS Comprehensive Cancer Center
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1038/bmt.2017.171
dc.relation.issn 0268-3369
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
bmt2017171.pdf 792.9Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record